Skip to main navigation

Skip to content
Skip to primary sidebar
Skip to footer

240.243.1201
info@glycomimetics.com

Careers
Contact Us

Investor Relations

About Us
Patients
- Clinical Trials
- Expanded Access
Pipeline
Science
Collaborations
Investors

Press Releases

Investor Relations

About Us
Patients
- Clinical Trials
- Expanded Access
Pipeline
Science
Collaborations
Investors

Press Releases

Year

May 3, 2023

GlycoMimetics Reports Highlights and Financial Results for First Quarter 2023

April 26, 2023

GlycoMimetics to Report First Quarter 2023 Financial Results on May 3, 2023

March 29, 2023

GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Year-end 2022

March 16, 2023

GlycoMimetics to Report Fourth Quarter and 2022 Full Year Financial Results on March 29, 2023

March 1, 2023

GlycoMimetics to Participate in Upcoming Cowen 43rd Annual Health Care Conference

February 16, 2023

GlycoMimetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

February 15, 2023

GlycoMimetics Announces Continuation of Phase 3 Study of E-selectin Antagonist Uproleselan in Relapsed/Refractory AML to Originally Planned Final Analysis Following Interim Analysis by Independent Data Monitoring Committee

February 6, 2023

GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Shareholder Tools

Print

Print
Printed Materials

Printed Materials
Email Alerts

Email Alerts
RSS

RSS
Search

Search

Footer

Questions?

Contact GlycoMimetics Today

©2023 GlycoMimetics All rights reserved. Website Design & Development: Graphic Beans

Site Map | Terms of Use | Privacy | Contact Us